Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Laurel J Mengle-Gaw"'
Autor:
Edward C Smith, Laurie S Conklin, Eric P Hoffman, Paula R Clemens, Jean K Mah, Richard S Finkel, Michela Guglieri, Mar Tulinius, Yoram Nevo, Monique M Ryan, Richard Webster, Diana Castro, Nancy L Kuntz, Laurie Kerchner, Lauren P Morgenroth, Adrienne Arrieta, Maya Shimony, Mark Jaros, Phil Shale, Heather Gordish-Dressman, Laura Hagerty, Utkarsh J Dang, Jesse M Damsker, Benjamin D Schwartz, Laurel J Mengle-Gaw, Craig M McDonald, CINRG VBP15 and DNHS Investigators
Publikováno v:
PLoS Medicine, Vol 17, Iss 9, p e1003222 (2020)
BackgroundTreatment with corticosteroids is recommended for Duchenne muscular dystrophy (DMD) patients to slow the progression of weakness. However, chronic corticosteroid treatment causes significant morbidities. Vamorolone is a first-in-class anti-
Externí odkaz:
https://doaj.org/article/b45ccb68e7754878b721301c83d6bdc1
Autor:
Michela Guglieri, Paula R. Clemens, Seth J. Perlman, Edward C. Smith, Iain Horrocks, Richard S. Finkel, Jean K. Mah, Nicolas Deconinck, Nathalie Goemans, Jana Haberlova, Volker Straub, Laurel J. Mengle-Gaw, Benjamin D. Schwartz, Amy D. Harper, Perry B. Shieh, Liesbeth De Waele, Diana Castro, Michelle L. Yang, Monique M. Ryan, Craig M. McDonald, Mar Tulinius, Richard Webster, Hugh J. McMillan, Nancy L. Kuntz, Vashmi K. Rao, Giovanni Baranello, Stefan Spinty, Anne-Marie Childs, Annie M. Sbrocchi, Kathryn A. Selby, Migvis Monduy, Yoram Nevo, Juan J. Vilchez-Padilla, Andres Nascimento-Osorio, Erik H. Niks, Imelda J.M. de Groot, Marina Katsalouli, Meredith K. James, Johannes van den Anker, Jesse M. Damsker, Alexandra Ahmet, Leanne M. Ward, Mark Jaros, Phil Shale, Utkarsh J. Dang, Eric P. Hoffman
Publikováno v:
JAMA Neurology, 79(10), 1005-1014. AMER MEDICAL ASSOC
Jama Neurology, 79, 10, pp. 1005-1014
Jama Neurology, 79, 1005-1014
Jama Neurology, 79, 10, pp. 1005-1014
Jama Neurology, 79, 1005-1014
ImportanceCorticosteroidal anti-inflammatory drugs are widely prescribed but long-term use shows adverse effects that detract from patient quality of life.ObjectiveTo determine if vamorolone, a structurally unique dissociative steroidal anti-inflamma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::725b0a040cb61b4b57e2cda4b26e1adf
http://hdl.handle.net/1887/3497485
http://hdl.handle.net/1887/3497485
Publikováno v:
Mediators of Inflammation, Vol 11, Iss 5, Pp 275-286 (2002)
The discovery of two isoforms of the cyclooxygenase enzyme, COX-1 and COX-2, and the development of COX-2-specific inhibitors as anti-inflammatories and analgesics have offered great promise that the therapeutic benefits of NSAIDs could be optimized
Externí odkaz:
https://doaj.org/article/c3407f2538124e068d8d2a8fda8c1ed9
Autor:
Benjamin D Schwartz, Heather Gordish-Dressman, C. McDonald, J. van den Anker, Diana Castro, Michael T. Ryan, J. Mah, Leanne M Ward, Yoram Nevo, Eric P. Hoffman, Nancy L. Kuntz, M. Guglieri, Utkarsh J. Dang, Paula R. Clemens, Richard S. Finkel, Jesse M. Damsker, Richard D. Webster, Mika Leinonen, Laurel J Mengle-Gaw, Edward C. Smith, Mar Tulinius
Publikováno v:
Neuromuscular Disorders. 31:S48
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e9674923075cf962abab64a466366db
https://doi.org/10.1016/j.nmd.2021.07.020
https://doi.org/10.1016/j.nmd.2021.07.020
Autor:
Jean K. Mah, Heather Gordish-Dressman, Diana Castro, Nancy L. Kuntz, Utkarsh J. Dang, Laurie S. Conklin, Dnhs Investigators, Jesse M. Damsker, Monique M. Ryan, Paula R. Clemens, Maya Shimony, Phil Shale, Eric P. Hoffman, Mar Tulinius, Richard Webster, Laurel J Mengle-Gaw, Michela Guglieri, Mark Jaros, Laurie Kerchner, Richard S. Finkel, Antonio Arrieta, Edward C. Smith, Craig M. McDonald, Yoram Nevo, Benjamin D Schwartz, Laura Hagerty, Lauren P. Morgenroth
Publikováno v:
PLoS Medicine
PLoS Medicine, Vol 17, Iss 9, p e1003222 (2020)
PLoS Medicine, Vol 17, Iss 9, p e1003222 (2020)
Background Treatment with corticosteroids is recommended for Duchenne muscular dystrophy (DMD) patients to slow the progression of weakness. However, chronic corticosteroid treatment causes significant morbidities. Vamorolone is a first-in-class anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c75b6d44d74183b16be3be6a55e6b4c
https://doi.org/10.1371/journal.pmed.1003222
https://doi.org/10.1371/journal.pmed.1003222
Autor:
Benjamin D Schwartz, Kanneboyina Nagaraju, Avital Cnaan, Andrea L. Smith, Katharine Bushby, Catherine Siener, Lauren P. Morgenroth, Michela Guglieri, Mark Jaros, Phil Shale, John M. McCall, Heather Gordish-Dressman, Laurel J Mengle-Gaw, Nancy L. Kuntz, Edward C. Smith, Jean K. Mah, Diana Castro, Jesse M. Damsker, Craig M. McDonald, John N. van den Anker, Laurie S. Conklin, Paula R. Clemens, Yoram Nevo, Eric P. Hoffman, Richard S. Finkel, Mar Tulinius, Antonio Arrieta, Maya Shimony, Monique M. Ryan, Richard D. Webster
Publikováno v:
Neurology
ObjectiveTo study vamorolone, a first-in-class steroidal anti-inflammatory drug, in Duchenne muscular dystrophy (DMD).MethodsAn open-label, multiple-ascending-dose study of vamorolone was conducted in 48 boys with DMD (age 4–ResultsOral administrat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4ac8ee470e10009787fc6003bae2474
https://pubmed.ncbi.nlm.nih.gov/31451516
https://pubmed.ncbi.nlm.nih.gov/31451516
Publikováno v:
Future Rheumatology. 1:661-672
Tacrolimus is an immunosuppressive drug that is approved and currently used primarily for the prophylaxis of liver, heart and kidney allograft rejection. Recently, oral tacrolimus 1.5–3 mg/day has been approved in Japan and Canada for the treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4de522974adce4d8f53d6d654d6633f
https://doi.org/10.2217/17460816.1.6.661
https://doi.org/10.2217/17460816.1.6.661
Autor:
Jeffrey L. Kaine, Mary Ann Borton, Jon T Stevenson, Daniel E. Furst, Benjamin D Schwartz, Wayne Wisemandle, David E. Yocum, Laurel J Mengle-Gaw, Andrew R. Baldassare, Qais A Mekki
Publikováno v:
Arthritis & Rheumatism. 48:3328-3337
Objective To evaluate the efficacy and safety of tacrolimus as monotherapy in controlling the signs and symptoms of patients with rheumatoid arthritis (RA). Methods This was a 6-month, phase III, double-blind, multicenter study. Patients with active
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8eaa5a1a9626f47bee87955f6d1d50cb
https://doi.org/10.1002/art.11363
https://doi.org/10.1002/art.11363
Autor:
Jeffrey L. Kaine, Benjamin D Schwartz, Wayne Wisemandle, Karen S. Kolba, Joel M. Kremer, Mary Ann Borton, Qais A Mekki, Joseph S Habros, Laurel J Mengle-Gaw
Publikováno v:
Arthritis & Rheumatism. 48:2763-2768
Objective To assess the safety of tacrolimus used in combination with oral methotrexate (MTX) to control the signs and symptoms of rheumatoid arthritis (RA) in patients whose disease remains active despite treatment with MTX. Methods This was a multi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7aaeec6e76f50eb52ecc75280886e0ea
https://doi.org/10.1002/art.11257
https://doi.org/10.1002/art.11257
Publikováno v:
Mediators of Inflammation
Mediators of Inflammation, Vol 11, Iss 5, Pp 275-286 (2002)
Mediators of Inflammation, Vol 11, Iss 5, Pp 275-286 (2002)
The discovery of two isoforms of the cyclooxygenase enzyme, COX-1 and COX-2, and the development of COX-2-specific inhibitors as anti-inflammatories and analgesics have offered great promise that the therapeutic benefits of NSAIDs could be optimized
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5eb9c87cbd1c3cc794346173b93ac990
https://doi.org/10.1080/09629350290000041
https://doi.org/10.1080/09629350290000041